Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117702 | 1.00 | CYP2C19 (0.39) | CYP2C19SLC6A2SLC6A4SLC6A3MMP2 | |
| SCHEMBL2423874 | 1.00 | CYP2C19 (0.39) | CYP2C19SLC6A2SLC6A4SLC6A3MMP2 | |
| Cadaverine Tartrate SCHEMBL18879377 | 0.90 | CYP2C19 (0.37) | CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29951019 | 0.88 | SLC6A2 (0.39) | CYP2C19SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL25962718 | 0.85 | SLC6A2 (0.40) | CYP2C19SLC6A2SLC6A4SLC6A3MMP2 | |
| Hydrochloric Acid SCHEMBL28328339 | 0.84 | SLC6A2 (0.40) | CYP2C19SLC6A2SLC6A4SLC6A3MMP2 | |
| SCHEMBL28230632 | 0.81 | CYP2C19 (0.39) | CYP2C19SLC6A2SLC6A4SLC6A3MMP2 | |
| SCHEMBL21937953 | 0.80 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3MMP2MMP14 | |
| SCHEMBL10088963 | 0.79 | — | — | |
| SCHEMBL2890720 | 0.79 | POLB (0.41) | SLC6A2SLC6A4SLC6A3MMP2MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110431142-A | Alicyclic substituted pyrazolo [1,5-a] pyrimidine derivatives of pharmacological activity | RICHTER GEDEON NYRT | 2019-11-08 | — | — | CN | disclosed |
| CN-110402245-A | Process for the separation of optical isomers of racemic 3-alkylpiperidine-carboxylic acid ethyl ester | RICHTER GEDEON NYRT | 2019-11-01 | — | — | CN | disclosed |
| EP-2430195-A2 | COMPOSITIONS AND METHODS FOR BIOLOGICAL SAMPLE STORAGE | Biomatrica, INC. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132508-A2 | COMPOSITIONS AND METHODS FOR BIOLOGICAL SAMPLE STORAGE | BIOMATRICA, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20080306054-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| CN-101263115-A | Substituted indoles and use thereof | WYETH CORP (US) | 2008-09-10 | — | — | CN | disclosed |
| EP-0931078-B1 | NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20060161004-A1 | Novel compounds | GLAXOSMITHKLINE SPA | 2006-07-20 | — | — | US | disclosed |
| US-20050070574-A1 | Novel compounds | GLAXOSMITHKLINE SPA AND LABORATOIRE | 2005-03-31 | — | — | US | disclosed |
| US-20040102633-A1 | Novel compounds | GLAXOSMITHKLINE S.P.A. (IT) | 2004-05-27 | — | — | US | disclosed |
| WO-2001004119-A1 | AMIDO SPIROPIPERIDINES PROMOTE THE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| US-5965570-A | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING THE ABNORMAL GROWTH OF CELLS; ADMINISTERING TO INHIBIT TUMOR CELLS WHEREIN THE RAS PROTEIN IS ACTIVATED AS A RESULT OF ONCOGENIC MUTATION IN GENES OTHER THAN THE RAS GENE | SCHERING CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0931078-A1 | NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998011098-A1 | NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-03-19 | — | — | WO | disclosed |
| EP-0522082-B1 | MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE | GLASKY ALVIN J (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0522082-A4 | MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE | — | 1993-06-09 | — | — | EP | disclosed |
| EP-0522082-A1 | MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE. | GLASKY ALVIN J (US) | 1993-01-13 | — | — | EP | disclosed |
| US-5091432-A | Synergistic | SPECTRUM PHARMACEUTICALS, INC. | 1992-02-25 | — | — | US | disclosed |
| WO-1991014434-A1 | MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE | GLASKY ALVIN J (US) | 1991-10-03 | — | — | WO | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070574-A1 | Novel compounds | NR1H3, NR1H2, CNR1 | CYP2C19 433/4885SLC6A2 1238/4885SLC6A4 804/4885 |
| US-20060161004-A1 | Novel compounds | SLC10A1, ABCB11, AQP1 | CYP2C19 88/4885SLC6A2 1414/4885SLC6A4 1587/4885 |
| US-20080306054-A1 | Pharmaceutical Compounds | HSP90AB1, HSP90AA1, HSP90AB2P | CYP2C19 173/4885SLC6A2 492/4885SLC6A4 806/4885 |
| US-20040102633-A1 | Novel compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, NR1H3 | CYP2C19 782/4885SLC6A2 1048/4885SLC6A4 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.